Skip to main content

Drug Interaction Report

2 potential interactions and/or warnings found for the following 2 drugs:

Add another drug
Filter by interaction and/or warning

Interactions between your drugs

Moderate

trimethoprim zalcitabine

Applies to: Proloprim (trimethoprim), zalcitabine

MONITOR: Trimethoprim may increase plasma concentrations and decrease clearance of zalcitabine. The mechanism may be inhibition of renal tubular secretion of zalcitabine. The clinical significance is unknown.

MANAGEMENT: Close clinical monitoring for evidence of zalcitabine toxicity (peripheral neuropathy, pancreatitis, lactic acidosis, hepatotoxicity) is recommended when these drugs are used together. In addition, a reduction in zalcitabine dosage may be warranted. Patients should be advised to promptly notify their doctor if they experience numbness, tingling, severe nausea and vomiting, diarrhea, abdominal pain, severe fatigue, or jaundice.

References

  1. "Multum Information Services, Inc. Expert Review Panel"
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Switch to consumer interaction data

Drug and food interactions

Minor

zalcitabine food

Applies to: zalcitabine

Zalcitabine bioavailability may be decreased by 14% if taken with meals. The mechanism and clinical significance are unknown.

References

  1. (2001) "Product Information. HIVID (zalcitabine)." Roche Laboratories

Switch to consumer interaction data

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer